Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 29 September 2017, 15:12 HKT/SGT
Share:
    

Source: Eisai
Eisai Presents Results of Phase Iii Trial of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma in Oral Session at 20th CSCO Annual Meeting
- Results of Subpopulation Analysis of Patients From Greater Chinese Region (Mainland China, Hong Kong, and Taiwan) -

TOKYO, Sept 29, 2017 - (JCN Newswire) - Eisai Co., Ltd. has announced that the results of a subpopulation analysis of patients from the Greater Chinese Region (mainland China, Hong Kong, and Taiwan) in a Phase III trial (REFLECT / Study 304)(1) of its in-house discovered and developed anticancer agent lenvatinib mesylate (product names: Lenvima / Kisplyx, "lenvatinib") versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma (HCC) were orally presented for the first time during the 20th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), which took place in Xiamen (Amoy) in the Fujian Province of China. Over half of the world's HCC patients come from the Greater Chinese Region.

In the subpopulation analysis, lenvatinib demonstrated efficacy based on extension of Overall Survival (OS) compared to sorafenib (nominal P = 0.026), with improvements also observed in Progression Free Survival (PFS), Time to Progression (TTP) and Objective Response Rate (ORR) (see table below). Approximately 80% of patients in the subpopulation were suffering from HCC resulting from chronic hepatitis B virus (HBV). For these patients, median OS in the lenvatinib group (123 patients) was 14.9 months, compared to 9.9 months in the sorafenib group (119 patients) (Hazard Ratio (HR) 0.72, 95% Confidence Interval (CI) = 0.53-0.97). These findings are consistent with the overall results of the Greater Chinese Region subpopulation. HBV is considered to be a negative predictor of tumor response to existing drug therapies. However, this data supports the effect of lenvatinib in patients with HCC resulting from HBV. Since there are many patients suffering from HCC resulting from HBV in the Greater Chinese Region, lenvatinib is expected to be a new treatment option for HCC patients in this area.

Liver cancer is the second leading cause of cancer related deaths and is estimated to be responsible for approximately 750,000 deaths per year globally. Additionally, approximately 780,000 cases are newly diagnosed each year, about 80% of which occur in Asian regions. Specifically, in China, there are approximately 395,000 new cases and 380,000 deaths per year, accounting for approximately 50% of cases worldwide.(2) HCC accounts for 85% to 90% of primary liver cancer cases. Treatment options for unresectable HCC are limited and the prognosis is very poor, making this an area of high unmet medical need.

Following submissions in Japan (June 2017), the United States and Europe (July 2017), Eisai will submit a regulatory application for lenvatinib in HCC in China within the latter half of fiscal 2017. Eisai remains committed to generating scientific evidence aimed at maximizing the value of lenvatinib as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

About lenvatinib mesylate (generic name, "lenvatinib", product name: Lenvima / Kisplyx)

Discovered and developed in-house, lenvatinib is an orally administered multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4) in addition to other proangiogenic and oncogenic pathway-related RTKs (including the platelet-derived growth factor (PDGF) receptor PDGFRalpha; KIT; and RET) involved in tumor proliferation. Currently, Eisai has obtained approval for lenvatinib as a treatment for refractory thyroid cancer in over 50 countries, including the United States, Japan, and in Europe. Additionally, Eisai has obtained approval for lenvatinib in combination with everolimus in the United States, Europe, and other countries, as a treatment for renal cell carcinoma (second-line). In Europe, lenvatinib was launched under the brand name Kisplyx for this indication. A Phase III study of lenvatinib in separate combinations with everolimus and pembrolizumab in renal cell carcinoma (first-line) is underway. A Phase Ib/II study to investigate the agent in combination with pembrolizumab in select solid tumors (endometrial cancer, non-small cell lung cancer, renal cell carcinoma, urothelial cancer, head and neck cancer, and melanoma) is underway. Additionally, a Phase Ib study of the agent in hepatocellular carcinoma is also underway.

About analysis of Greater Chinese Region subpopulation in REFLECT study

The results presented were based on a subpopulation analysis of 288 patients from the Greater Chinese Region (mainland China: 213, Hong Kong: 21, Taiwan: 54) out of the 954 HCC patients that participated in the REFLECT study. The subpopulation analysis revealed the following results: OS (lenvatinib 15.0 months versus sorafenib 10.2 months in median, HR 0.73, 95% CI = 0.55-0.96, nominal P=0.026), PFS (lenvatinib 9.2 months versus sorafenib 3.6 months in median, HR 0.55, 95% CI = 0.42-0.72, nominal P=0.00001), TTP (lenvatinib 11.0 months versus sorafenib 3.7 months in median, HR 0.53, 95% CI = 0.40-0.71, nominal P=0.00001) and ORR (lenvatinib 21.5% versus sorafenib 8.3%, odds ratio 3.17, 95% CI = 1.54-6.53, nominal P=0.0014). Additionally, of the 288 patients in the subpopulation, approximately 80% (n = 231) were suffering from HCC resulting from HBV. An analysis of these patients revealed the following results: OS (lenvatinib [n = 123] 14.9 months versus sorafenib [n = 119] 9.9 months in median, HR 0.72, 95% CI = 0.53-0.97) and PFS (lenvatinib 9.2 months versus sorafenib 3.5 months in median, HR 0.52, 95% CI = 0.38-0.70). Additionally, lenvatinib's safety profile for the Greater Chinese Region subpopulation was consistent with previous studies.

About lenvatinib mesylate (generic name, "lenvatinib", product name: Lenvima / Kisplyx)
Discovered and developed in-house, lenvatinib is an orally administered multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4) in addition to other proangiogenic and oncogenic pathway-related RTKs (including the platelet-derived growth factor (PDGF) receptor PDGFRalpha; KIT; and RET) involved in tumor proliferation. Currently, Eisai has obtained approval for lenvatinib as a treatment for refractory thyroid cancer in over 50 countries, including the United States, Japan, and in Europe. Additionally, Eisai has obtained approval for lenvatinib in combination with everolimus in the United States, Europe, and other countries, as a treatment for renal cell carcinoma (second-line). In Europe, lenvatinib was launched under the brand name Kisplyx for this indication. A Phase III study of lenvatinib in separate combinations with everolimus and pembrolizumab in renal cell carcinoma (first-line) is underway. A Phase Ib/II study to investigate the agent in combination with pembrolizumab in select solid tumors (endometrial cancer, non-small cell lung cancer, renal cell carcinoma, urothelial cancer, head and neck cancer, and melanoma) is underway. Additionally, a Phase Ib study of the agent in hepatocellular carcinoma is also underway.

About analysis of Greater Chinese Region subpopulation in REFLECT study

The results presented were based on a subpopulation analysis of 288 patients from the Greater Chinese Region (mainland China: 213, Hong Kong: 21, Taiwan: 54) out of the 954 HCC patients that participated in the REFLECT study. The subpopulation analysis revealed the following results: OS (lenvatinib 15.0 months versus sorafenib 10.2 months in median, HR 0.73, 95% CI = 0.55-0.96, nominal P=0.026), PFS (lenvatinib 9.2 months versus sorafenib 3.6 months in median, HR 0.55, 95% CI = 0.42-0.72, nominal P=0.00001), TTP (lenvatinib 11.0 months versus sorafenib 3.7 months in median, HR 0.53, 95% CI = 0.40-0.71, nominal P=0.00001) and ORR (lenvatinib 21.5% versus sorafenib 8.3%, odds ratio 3.17, 95% CI = 1.54-6.53, nominal P=0.0014). Additionally, of the 288 patients in the subpopulation, approximately 80% (n = 231) were suffering from HCC resulting from HBV. An analysis of these patients revealed the following results: OS (lenvatinib [n = 123] 14.9 months versus sorafenib [n = 119] 9.9 months in median, HR 0.72, 95% CI = 0.53-0.97) and PFS (lenvatinib 9.2 months versus sorafenib 3.5 months in median, HR 0.52, 95% CI = 0.38-0.70). Additionally, lenvatinib's safety profile for the Greater Chinese Region subpopulation was consistent with previous studies.

(1) Cheng A et al. "Phase 3 trial of lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma", the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), (June 2017), Abstract No: 4001
(2) GLOBOCAN2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/


About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Sept 29, 2017 15:12 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Oct 13, 2017 09:48 HKT/SGT
Eisai: Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25mg in Japan
Oct 11, 2017 11:48 HKT/SGT
Small and Easy to Take, Just One Tablet per Dose Eisai to Launch "Onji-No-Megumi" for Improving Forgetfulness in Middle Age and Beyond
Oct 4, 2017 09:49 HKT/SGT
Eisai and Biotoscana Sign Exclusive Licensing Agreement for Latin America
Oct 3, 2017 14:11 HKT/SGT
Sato Pharmaceutical and Eisai to Co-Promote New Oral Antifungal Agent Containing Active Ingredient Fosravuconazole in Japan
Sept 27, 2017 12:25 HKT/SGT
Eisai: Application for Additional Indication of Lenvima for Hepatocellular Carcinoma Accepted for Review by U.S. FDA
Sept 22, 2017 15:46 HKT/SGT
Eisai: Additional Dosage and Administration of Proton Pump Inhibitor Pariet 5 mg Tablets, 10 mg Tablets Approved in Japan for Maintenance Therapy of Proton Pump Inhibitor Resistant Reflux Esophagitis
Sept 22, 2017 09:56 HKT/SGT
Eisai Presents Latest Non-Clinical Data on Its First Antibody-Drug Conjugate MORAb-202 at 8th Annual World ADC
Sept 19, 2017 09:01 HKT/SGT
Eisai Presents Results of Phase Iii Clinical Study of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma at 11th ILCA Annual Conference
Sept 13, 2017 13:25 HKT/SGT
Eisai to Launch New "Etak Antimicrobial Spray Alpha" Containing Long-Acting Antimicrobial Agent Etak
Sept 12, 2017 23:06 HKT/SGT
Eisai and Mamorio to Jointly Launch "Me-Mamorio" Tracking Tool to Support People with Dementia and Seniors Going Out
More news >>
 News Alerts
Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: